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Abstract
Prediction of clinical drug response (CDR) of cancer patients, based on their clinical and
molecular profiles obtained prior to administration of the drug, can play a significant role in
individualized medicine. Machine learning models have the potential to address this issue
but training them requires data from a large number of patients treated with each drug, limit-
ing their feasibility. While large databases of drug response and molecular profiles of preclin-
ical in-vitro cancer cell lines (CCLs) exist for many drugs, it is unclear whether preclinical
samples can be used to predict CDR of real patients. We designed a systematic approach
to evaluate how well different algorithms, trained on gene expression and drug response of
CCLs, can predict CDR of patients. Using data from two large databases, we evaluated vari-
ous linear and non-linear algorithms, some of which utilized information on gene interac-
tions. Then, we developed a new algorithm called TG-LASSO that explicitly integrates
information on samples’ tissue of origin with gene expression profiles to improve prediction
performance. Our results showed that regularized regression methods provide better pre-
diction performance. However, including the network information or common methods of
including information on the tissue of origin did not improve the results. On the other hand,
TG-LASSO improved the predictions and distinguished resistant and sensitive patients
for 7 out of 13 drugs. Additionally, TG-LASSO identified genes associated with the drug
response, including known targets and pathways involved in the drugs’ mechanism of
action. Moreover, genes identified by TG-LASSO for multiple drugs in a tissue were associ-
ated with patient survival. In summary, our analysis suggests that preclinical samples can
be used to predict CDR of patients and identify biomarkers of drug sensitivity and survival.
Author summary
Cancer is among the leading causes of death globally and prediction of the drug response
of patients to different treatments based on their clinical and molecular profiles can enable
individualized cancer medicine. Machine learning algorithms have the potential to play a
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significant role in this task; however, these algorithms are designed based on the premise
that a large number of labeled training samples are available, and these samples are accu-
rate representations of the profiles of real tumors. However, due to ethical and technical
reasons, it is not possible to screen humans for many drugs, significantly limiting the size
of training data. To overcome this data scarcity problem, machine learning models can be
trained using large databases of preclinical samples (e.g. cancer cell line cultures). How-
ever, due to the major differences between preclinical samples and real tumors, it is
unclear how accurately such preclinical-to-clinical computational models can predict the
clinical drug response of cancer patients. Here, first we systematically evaluate a variety of
different linear and nonlinear machine learning algorithms for this particular task using
two large databases of preclinical (GDSC) and tumor samples (TCGA). Then, we present
a novel method called TG-LASSO that utilizes a new approach for explicitly incorporating
the tissue of origin of samples in the prediction task. Our results show that TG-LASSO
outperforms all other algorithms and can distinguish resistant and sensitive patients for
the majority of the tested drugs. Follow-up analysis reveal that this method can also iden-
tify biomarkers of drug sensitivity in each cancer type.
Introduction
Cancer is one of the leading causes of death globally and is expected to be the most important
obstacle in increasing the life expectancy in the 21st century [1]. Individualized cancer medi-
cine has the potential to revolutionize patient prognosis; however, two major challenges in this
area include the prediction of the individual responses to different treatments and the identifi-
cation of molecular biomarkers of drug sensitivity. While factors such as cancer type or its
symptoms have been traditionally used to identify the treatment [2], the development of high
throughput sequencing technologies [3] and sophisticated machine learning (ML) approaches
present the possibility of individualizing treatment based on molecular ‘omics’ profiles of
patients’ tumors [4]. However, due to the technical and ethical challenges of screening individ-
uals against many drugs [5], such models are either trained for only a handful of drugs [6] or
are trained using preclinical samples such as 2D cancer cell line cultures (CCLs) [7–10]. In
spite of the success of these methods in predicting the drug response of left-out preclinical sam-
ples using models trained on preclinical samples, they have had limited success in predicting
the CDR of real patients [9, 11], with some exceptions [12–14].
Various preclinical models of cancer have been developed to enable the study of cancer and
its treatment in the laboratory. CCLs, which are 2D cell cultures developed from tumor sam-
ples, are one of the least expensive and most studied of these models. Recently, several large-
scale studies have cataloged the molecular profiles of thousands of CCLs and their response to
hundreds of drugs [15–17]. Although various computational models have been developed to
predict the CCLs’ drug response using their molecular profiles [7–9], these models have shown
limited success in predicting CDR in real patients. In spite of sporadic successes for a handful
of drugs [12, 13], the current belief remains that developing an accurate computational ‘pre-
clinical-to-clinical’ model is extremely difficult if not impossible [5]. Our goal in this study
was to perform an unbiased systematic evaluation on a panel of drugs to determine 1) whether
regression models trained on in vitro preclinical samples can predict the CDR of real patients
for each drug and 2) what type of side information (e.g. interaction of the genes, the tissue of
origin of samples) might improve the CDR prediction.
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To this end, we first formed a computational framework to systematically evaluate the pre-
diction accuracy of different computational methods. We obtained preclinical training sam-
ples from the Genomics of Drug Sensitivity in Cancer (GDSC) database [16] and obtained
molecular profiles of tumor samples from The Cancer Genome Atlas (TCGA) [18]. We
focused on drugs that were shared between these two datasets and utilized the gene expression
profiles of samples to predict the drug response, since previous studies have demonstrated
gene expression to be most informative for this task [7]. Our analysis showed that regularized
linear regression models provide the best performance among various algorithms. In addition,
we included prior information on the relationship among genes (in the form of gene interac-
tion networks) using several algorithms; however, this prior information did not improve the
prediction.
Next, we developed a novel approach called Tissue-Guided LASSO (TG-LASSO) to explic-
itly include information on the tissue of origin of samples in the regularized regression model.
This method outperformed all other approaches evaluated. Using this method, we showed that
the CDR of cancer patients can be predicted using preclinical CCL training samples, for the
majority of drugs. More specifically, out of 12 drugs, TG-LASSO separated resistant patients
from sensitive patients for 7 drugs. In addition, for each tissue type and drug, TG-LASSO iden-
tified a small set of genes that may be used as tissue-specific biomarkers of drug response for
each drug. We showed that genes selected by TG-LASSO for prediction of drug response are
informative of patient survival when used as a gene signature, and also provide pathway-level
insights into mechanisms of drug action. These results emphasize the clinical relevance of
molecular profiles of preclinical samples cataloged in large-scale databases and demonstrate
the importance of properly including information on the lineage of samples in follow-up
analyses.
Results
Prediction of clinical drug response of cancer patients using in vitro
experiments on preclinical cancer cell lines
In this study, our first goal was to determine whether commonly used machine learning algo-
rithms are capable of predicting the clinical drug response (CDR) in cancer patients using
computational models trained only on cancer cell lines’ (CCLs) basal gene expression profiles
(i.e. before administration of the drug) and their drug response. For this purpose, we identified
23 drugs (Supplementary S1 Table) that were administered to patients of The Cancer Genome
Atlas (TCGA) [18] and were also present in the Genomics of Drug Sensitivity in Cancer
(GDSC) [16] database. We obtained the gene expression profiles of 531 primary tumor sam-
ples of TCGA patients (17 different cancer types) who were administered any of these drugs
from the Genomic Data Commons [19] (see Methods and Supplementary S1 Table). We
obtained the carefully collected and curated information on clinical drug response (CDR) of
these patients from [6]. Similarly, we obtained the gene expression profiles and the logarithm
of half-maximal inhibitory concentration (log (IC50)) of 979 cancer cell lines (of 55 different
tissues) from GDSC (see Supplementary S1 Table for the number of cell lines from each
tissue).
We formed a computational framework to systematically evaluate the prediction capability
of different algorithms (Fig 1). In this framework, we first normalize the data and remove
batch effects to ensure that the gene expression profiles from these two datasets are comparable
(Methods). This is particularly important since GDSC contains microarray gene expression
values, while TCGA contains RNA-seq data. We used ComBat [20] for batch effect removal,
which has been previously used to successfully remove the batch effect between RNA-seq and
Clinical drug response prediction using TG-LASSO
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microarray data [21] (see Supplementary S1 Fig for the distribution of samples before and
after batch effect removal). Note that the CDR of the test samples were not used during this
step. Next, we trained a regression model to relate the gene expression profiles of CCLs to their
log (IC50) values for a specific drug. Given this model, we then estimated log (IC50) values for
different patient tumors using their gene expression profiles. Finally, we compared the esti-
mated log (IC50) values to the true CDR of the tumors of patients treated with the same drug
to determine the accuracy of prediction.
We used a one-sided nonparametric Mann Whitney U test to determine whether the esti-
mated log(IC50) values of resistant tumors (those with CDR of ‘clinical progressive disease’
or ‘stable disease’) are significantly larger than sensitive tumors (those with CDR of ‘partial
response’ or ‘complete response’). One should note that due to the difference in the type of
measured drug response in the training set (continuous-valued log(IC50)) and the test set
Fig 1. The pipeline used for prediction of clinical drug response of cancer patients using computational models
trained on gene expression and drug response of preclinical cell line samples. The input gene expression data (A)
corresponding to cancer cell lines (training set) and patients’ tumors (test set) are first homogenized and their batch-
effect is removed. The homogenized gene expression training data (B) and the cell lines’ log (IC50) values are used to
train a regression model (C). The trained model is applied to gene expression profiles of patients’ tumors to predict
their log (IC50) values, which are then used to evaluate the prediction performance (D).
https://doi.org/10.1371/journal.pcbi.1007607.g001
Clinical drug response prediction using TG-LASSO
PLOS Computational Biology | https://doi.org/10.1371/journal.pcbi.1007607 January 22, 2020 4 / 22
(categorical CDR), such an approach is necessary and other measures of performance such
as concordance index or mean squared error are not suitable. In this evaluation, we only used
12 drugs that had at least 2 tumor samples in each category of resistant or sensitive and had at
least 8 total samples with known CDR. Table 1 shows a summary of the performance of differ-
ent methods. In this table, we used the combined p-value of all 12 drugs (using Fisher’s method
to combine p-values) as a measure to summarize the results of different methods. Table 2 and
Supplementary S2 Table contain the detailed performance of LASSO and all other methods,
respectively, for prediction of the CDR of each drug. We focused on these methods as they
have been previously used for this task (but for fewer drugs and using other datasets), with dif-
ferent degrees of success [12, 22, 23]. Recently, [5] reported a computational model based on
ridge regression to predict the CDR of TCGA patients using GDSC training samples. Table 1
also includes the performance of this method using our evaluation, based on the predictions
reported in the original paper.
Table 1. The performance of different algorithms in predicting the CDR of patients using models trained on preclinical CCL samples. The second column shows
the properties of the algorithm (linear versus nonlinear; single task versus multi-task learning). The third column shows the number of drugs for which a statistically signif-
icant discrimination between resistant and sensitive patients was obtained (one-sided Mann Whitney U test). The fourth column shows the total number of drugs included
in the evaluation, and the fifth column shows the combined p-value (using Fisher’s method) for all the drugs in the analysis.
Algorithm Properties Drugs with P<0.05 Drugs Combined P (Fisher)
LASSO Linear, Single task 5 12 5.21E-09
ElasticNet Linear, Single task 5 12 1.18E-08
MTL-LASSO Linear, Multi-task 5 12 3.64E-06
Ridge Linear, Single task 4 12 1.75E-05
MTL-ElasticNet Linear, Multi-task 3 12 4.83E-06
SVR (Linear Kernel) Linear, Single task 3 12 1.10E-05
SVR (Polynomial Kernel) Nonlinear, Single task 3 12 1.82E-05
SVR (RBF kernel) Nonlinear, Single task 3 12 2.92E-05
K-Nearest Neighbor Nonlinear, Single task 3 12 8.26E-05
Multi-Layer Perceptron Nonlinear, Single task 2 12 4.86E-02
Gelhar, et al. (2017) Linear, Single task 1 11 1.85E-02
Random Forest Nonlinear, Single task 1 12 0.19
https://doi.org/10.1371/journal.pcbi.1007607.t001
Table 2. The performance of LASSO algorithm in predicting the CDR of patients using models trained on preclinical CCL samples. The second column shows the
p-value (one-sided Mann Whitney U test) for the predicted log (IC50) values of sensitive and resistant tumors. The third and fourth columns show the number of resistant
and sensitive tumors used in the statistical test.
Drug P-value (one-sided) Num Resistant (PD or SD) Num Sensitive (CR or PR)
bicalutamide 0.34 3 14
bleomycin 0.10 4 46
cisplatin 6.67E-05 25 111
docetaxel 0.98 17 55
doxorubicin 3.42E-03 7 54
etoposide 7.57E-04 10 71
gemcitabine 0.14 43 37
paclitaxel 0.62 28 74
sorafenib 0.19 13 2
tamoxifen 8.82E-03 4 14
temozolomide 9.08E-02 84 11
vinorelbine 2.10E-03 6 23
https://doi.org/10.1371/journal.pcbi.1007607.t002
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These results suggest several important points. First, consistent with the reports in [12, 22],
we observed that regularized linear models resulted in the best performance, with LASSO per-
forming the best. Second, we observed that although the method proposed in [5] is based on
ridge regression, its performance is inferior to the ridge regression utilized in our study. This
is likely due to the difference between the preprocessing and batch effect removal approaches
used in the two studies. More specifically, instead of using ComBat to homogenize the gene
expression data in the preclinical and clinical samples (as was done in our study and also in
[12]), they simply standardized the mean of each gene to zero and its variance to one. This
point emphasizes the importance of data preprocessing in pharmacogenomics studies. Third,
we observed that for some drugs, the CDR could be predicted independent of the method,
while for others, the choice of the method is important. For example, the CDR of cisplatin
could be predicted (p<0.05) using ten out of the twelve methods above (as an example Table 3
shows that 92% of resistant patients are correctly designated using LASSO, while keeping pre-
cision at ~30% and specificity at ~50%). As another example, the majority of the methods
could not predict the CDR of taxane-based chemotherapy agents (docetaxel and paclitaxel).
We suspect that this lack of success is due to the existence of various parameters that influence
their response, such as tissue dependence or microenvironmental factors [25, 26], which may
not be captured using these simple methods trained on gene expression profiles of CCLs. In
fact, we later show that including the tissue of origin explicitly in the predicting model using
TG-LASSO can significantly improve the drug response prediction for paclitaxel.
Including information on gene interactions does not improve CDR
prediction
Various studies have suggested that including information on the interaction of the genes (and
their protein products) or their involvement in different pathways can improve the accuracy of
different bioinformatics tasks [27] such as gene prioritization [28], gene function prediction
[29], gene set characterization [30], and tumor subtyping [31]. Since the genes (and their
protein products) involved in a drugs mechanism of action biochemically and functionally
interact with each other, we sought to determine whether including these interactions could
improve CDR prediction. Since linear models provided the best performance in our prelimi-
nary analyses (Table 1), we focused on methods that incorporate gene interaction networks
into linear predictive models. These included Generalized Elastic Net (GELnet) [32], Net-
work-Induced Classification Kernels (NICK) [33], Sparse Group LASSO (SGL) [34], as well
as a method based on LASSO combined with single sample gene set enrichment analysis
(ssGSEA) [35] (see Methods). In all cases, we used four gene interaction networks: an experi-
mentally verified network of protein-protein and genetic interactions, a gene co-expression
network, and a network built based on text mining from the STRING database [36], as well as
the HumanNet integrated network [37] (see Methods and Supplementary S1 Table for details).
Table 4 summarizes the results and Supplementary S3 Table provides the details of the evalua-
tions. These results suggest that in this application, incorporating network information using
Table 3. The contingency table of predictions using LASSO for cisplatin. The predicted log(IC50) values were
labeled as resistant or sensitive based on the threshold that obtained the highest oddsratio [24] (oddsratio = 10.5,
p<0.001).
Predicted Resistant Predicted Sensitive Total
True Resistant 23 2 25
True Sensitive 58 53 111
Total 81 55 136
https://doi.org/10.1371/journal.pcbi.1007607.t003
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these methods does not improve the prediction compared to linear models (e.g. LASSO) that
do not incorporate such information (Table 1). This was in spite of the fact that some of these
network-guided methods (e.g. NICK with STRING Text Mining) do improve the performance
of within-dataset cross-validation (using only GDSC samples) compared to LASSO (see Sup-
plementary Methods in S1 Text).
Incorporating the tissue of origin to improve CDR prediction
Up to this point, we only used the tissue of origin of the preclinical and clinical samples implic-
itly (through their gene expression profiles) by training a single model for a drug on all CCLs
of different lineages, and then using this global model to predict the response of patients with
different cancer types. However, due to the importance of the tissue of origin in the efficacy of
anticancer drugs observed in various studies [38–40] and its inclusion as auxiliary information
in some drug response prediction studies [9, 41, 42], we sought to determine whether explicitly
including the tissue of origin would improve the prediction of CDR, and if so, the best method
for this inclusion. For our analysis, we focused on variations of LASSO (without including
gene interactions), which previously yielded the best performance among all the tested algo-
rithms (Table 1). We matched the lineage of the CCLs with those of cancer patients, identify-
ing 13 shared tissue types.
One of the most common methods of including the tissue of origin in regression analysis is
introducing new binary features to each sample, representing whether the sample belongs to
that tissue (‘1’) or not (‘0’) [15]. We included 13 such binary features in the analysis (‘method
1’). However, the prediction results of this approach were almost identical to the results of
LASSO when not including any tissue information. This is not surprising, since in this applica-
tion the number of one type of features (i.e. genes) is much larger than the number of the
other type of features (i.e. tissue types). As a result, the predicted drug response values will be
highly biased by the influence of gene expression data and the tissue of origin’s influence will
be overlooked. As an alternative, we trained different LASSO models for each tissue type by
Table 4. The performance of network-based algorithms in predicting the CDR of patients using models trained on preclinical CCL samples. The third column
shows the number of drugs for which a statistically significant discrimination between resistant and sensitive patients was obtained (one-sided Mann Whitney U test). The
fourth column shows the total number of drugs included in the evaluation, and the fifth column shows the combined p-value (using Fisher’s method) for all the drugs in
the analysis. As a point of comparison, LASSO without the use of any network yielded p-value< 0.05 for five of 12 drugs, with combined p-value of 5.21E-09 (Table 1).
Network Algorithm Drugs with P<0.05 Drugs Combined P (Fisher)
STRING PPI NICK 5 12 1.79E-06
GELnet 5 12 1.21E-04
SGL 3 12 1.75E-05
ssGSEA-LASSO 3 12 6.94E-06
STRING Co-Expression NICK 5 12 2.40E-06
GELnet 5 12 1.07E-04
SGL 2 12 2.62E-04
ssGSEA-LASSO 4 12 1.40E-2
STRING Text Mining NICK 5 12 2.14E-06
GELnet 5 12 1.23E-04
SGL 3 12 7.95E-05
ssGSEA-LASSO 3 12 2.57E-02
HumanNet Integrated Network NICK 5 12 1.09E-06
GELnet 5 12 1.21E-04
SGL 3 12 7.69E-04
ssGSEA-LASSO 4 12 6.06E-07
https://doi.org/10.1371/journal.pcbi.1007607.t004
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restricting the training (CCL) and test (tumor) samples to those originating from the same tis-
sue of interest (‘method 2’). For tumor samples without CCLs with matching tissue, we used
all CCLs to train the model. This method resulted in poor performance, with only one drug
having a significant p-value and a combined p-value (Fisher’s method) of 0.16. The reason
behind this poor performance is the small number of samples in training each model: due to
the tissue-specificity condition imposed above, only a small fraction of the total samples are
used in training each model, which results in poor generalizability of the models.
To overcome these issues, while explicitly incorporating information on the samples’ tissue
of origin, we devised a new approach called Tissue-Guided LASSO (TG-LASSO). The idea
behind this approach is to use all CCLs originating from different tissue types in training the
LASSO model, but choose the hyperparameter of the LASSO model, α, in a tissue-dependent
manner (Fig 2). This avoids the issues caused by the small number of training samples in
Method 2, while adding a tissue-dependent aspect to the training of the model. Since α con-
trols the number of features (i.e. genes) used by the LASSO model, this approach allows us to
optimally select the number of predictive genes for each tissue type (see Methods for details)
yet use all CCLs to train these tissue-dependent regression models.
This approach resulted in the best performance among all the methods tested, with 7
(out of 12) drugs showing significant discrimination between resistant and sensitive tumors
(p<0.05) and a combined p-value (Fisher’s method for all 12 drugs) of 2.25E-10 (Fig 3, Table 5
Fig 2. The TG-LASSO pipeline. The steps of TG-LASSO are depicted for one tissue type. These steps are repeated for
each tissue type. To predict the drug response of tumors corresponding to tissue t, the cell lines of the same lineage are
identified (A). These cell lines are used as the validation set, while cell lines of all other lineages are used as the training
set for hyperparameter tuning (B). The identified hyperparameter is used to train a tissue-dependent model using all
the CCLs (C). The trained model is used to predict the drug response of tumors from tissue t (D). Since the
hyperparameter is tuned in a tissue-dependent manner (B and C), the models trained for each tissue type are distinct
(C and D).
https://doi.org/10.1371/journal.pcbi.1007607.g002
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Fig 3. The drug response prediction performance of seven drugs for which TG-LASSO predictions separated
sensitive patients from resistant (p< 0.05). A) The box plots reflect the distribution of estimated log (IC50) values
using TG-LASSO for each group of resistant or sensitive patients. The p-values correspond to a one-sided Mann-
Whitney U test. The Precision@20% (written as P@20%) is the precision of the method when samples with the
predicted log (IC50) above 80th percentile of the training log(IC50) values are declared as resistant and those below the
20th percentile are declared as sensitive. B) The Precision@k% as a function of k.
https://doi.org/10.1371/journal.pcbi.1007607.g003
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and Supplementary S4 Table). These results not only show that including the tissue of origin
can improve CDR prediction using preclinical samples, but also suggest that the method of uti-
lizing this information has a significant influence on the performance.
To better assess the ability of TG-LASSO in predicting whether a drug should be adminis-
tered to a patient or not, we defined a measure which we called Precision@k%. Intuitively, this
measure represents the precision of the method when test samples with predicted log(IC50)
above the (100—k)th percentile of the training samples’ log(IC50)s are labeled as resistant and
those below the kth percentile are labeled as sensitive (see Methods for details). Five drugs
(bicalutamide, cisplatin, etoposide, vinorelbine and temozolomide) had a Precision@20%
equal to 100% and the average value of this measure for all drugs was equal to 80% (see Fig 3B
and Supplementary S4 Table). These results suggest that the 20th and 80th percentiles of the
training samples’ log (IC50) may be good thresholds for deciding whether a patient is sensitive
or resistant to these drugs.
One interesting observation was that paclitaxel, the response of which could not be pre-
dicted accurately with the majority of methods reported in Table 1, showed a significant
improvement in the response prediction with TG-LASSO (p = 0.048, one-sided Mann Whit-
ney U test), suggesting a prominent role for the tissue of origin in its drug response. On the
other hand, the CDR prediction of docetaxel did not improve (p = 0.99), even though doce-
taxel is also a taxane, like paclitaxel, and these two drugs have a statistically significant corre-
lation in their CCL responses (Spearman rank correlation = 0.38, p = 1.7E-13). We suspected
that this difference between the performance of TG-LASSO for docetaxel and paclitaxel is
related to how well the CCL panel used for training represents the tumor samples of patients
to whom these drugs were administered. To evaluate this, we calculated the similarity
between the gene expression profiles of tumor samples to those of CCLs from the same tissue
of origin for these drugs. This analysis showed a lower similarity between the docetaxel-
administered tumors and CCLs (average cosine similarity = 0.07) compared to paclitaxel-
administered tumors and CCLs (average cosine similarity = 0.11). These results provide
evidence in favor of our hypothesis that the difference in the performance of TG-LASSO is
related to how well the CCLs represent the profile of tumors to which these two drugs were
administered.
Since some of the drugs used in our study were administered in combination with other
drugs, we asked how well TG-LASSO predicts the CDR in such cases of treatment with drug
combinations. For this purpose, we evaluated its CDR prediction for a drug only on patients
for whom that drug was administered over a period overlapping their treatment with at least
one other drug. We limited our analysis to 9 drugs with at least two samples (patients) in
each group (sensitive and resistant) and with at least 8 samples in total. Supplementary S5
Table shows that, consistent with our previous results, TG-LASSO outperforms all other
methods, capable of predicting the CDR of 6 (out of 9) drugs (p<0.05, one-sided Mann
Whitney U test).
Table 5. The prediction performance of different approaches that incorporate information on tissue of origin in LASSO. The second column shows which subset of
the training samples were used for training. The third column shows how tissue information was used. The fourth column shows the number of drugs for which a statisti-
cally significant discrimination between resistant and sensitive patients was obtained (one-sided Mann Whitney U test). The fifth column shows the total number of drugs
included in the evaluation, and the sixth column shows the combined p-value (using Fisher’s method) for all the drugs in the analysis.
Algorithm Training Samples Tissue information Drugs with P<0.05 Drugs Combined P (Fisher)
TG-LASSO All samples Used during hyperparameter tuning 7 12 2.25E-10
Method 1 All samples Used as new binary features 5 12 5.21E-09
Method 2 Only samples matching the test samples’ tissue Used to identify relevant training samples 1 12 0.16
https://doi.org/10.1371/journal.pcbi.1007607.t005
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Next, we sought to evaluate the effect of batch-effect removal and preprocessing on the per-
formance of TG-LASSO. For this purpose, we did not perform ComBat data homogenization
or z-score normalization on the gene expression data. As expected, the performance of both
TG-LASSO and LASSO deteriorated, with the former resulting in 4 drugs with p< 0.05 and
the latter with only 3 (Supplementary S6 Table). In spite of this, TG-LASSO still performed
better than LASSO, emphasizing the importance of including the tissue information.
Characterization of genes identified by TG-LASSO
During its training phase, TG-LASSO automatically selects a subset of genes to be used in the
regression model by tuning the hyperparameter α introduced above. The number of genes
selected in this manner depends on the drug and tissue type for which the model is trained to
make response predictions and was found to range between 9 and 808 genes with a median of
174 genes. The genes identified by TG-LASSO included many direct targets of each drug. (For
these analyses we used all 23 drugs shared between TCGA and GDSC and not just those with a
large number of samples in TCGA). For example, EGFR, which is a direct target of both cetux-
imab and gefitinib [43], was selected by this algorithm when trained to predict response of
these drugs in each of the 13 tissue types (Supplementary S7 Table). Similarly, FLT3, a target of
the drugs sorafenib and sunitinib [43], was selected by TG-LASSO for predicting response to
these drugs in 13 and 12 tissues, respectively. In addition to direct targets, many of the identi-
fied genes have been shown to be indirect targets of these drugs and to be involved in their
mechanism of action. For example DNER, a gene identified by TG-LASSO for all tissue types
for cisplatin (but was not identified by LASSO for this drug), has been shown to be signifi-
cantly upregulated in response to this drug in NCI-H526 cell lines [44].
More importantly, the knockdown or overexpression of many of the identified genes has
been shown to influence the sensitivity of cancer cells to these drugs. For example, the shRNA
knockdown of CHI3L1, a gene identified for etoposide and cisplatin response in every tissue
(but was not identified using LASSO for any of these drugs), has been shown to sensitize gli-
oma cells to these two drugs, while its overexpression reduced their sensitivity [45]. As another
example, the knockdown of SALL4 (identified in all tissues) in cancer cell lines has been
shown to increase the sensitivity of lung cancer cells [46] and esophageal squamous cell carci-
noma cells [47] to cisplatin. Supplementary S8 Table summarizes some of the evidence we
curated from literature for the role of different genes identified by TG-LASSO in all tissue
types for cisplatin (and whether they could have been identified using LASSO or not), as an
illustration. These examples show the fact that the genes utilized by TG-LASSO in prediction
of CDR of patients not only include targets of respective drugs, but also include genes whose
expression has been experimentally shown to predict the sensitivity of these drugs: a property
necessary for any predictive model of drug response. In addition, many of these genes could
not be identified by simply using LASSO.
Genes identified for multiple drugs in a tissue are associated with patient
survival
We hypothesized that genes that were identified by TG-LASSO as response predictors of many
drugs in a single tissue (Supplementary S9 Table) may be able to predict the survival of patients
who have cancer that originated from that tissue, as they may play a significant role in the
development and progress of the disease. To test this, we obtained gene expression values of
4908 primary tumors from 10 different cancer types (corresponding to the tissue types in our
study) from TCGA, requiring the data to include at least 170 patients and 20 incidents of
deaths for each cancer type (Supplementary S10 Table). Then, we clustered the primary
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tumors of each cancer type into two groups based on the expression of genes identified by
TG-LASSO for more than 5 different drugs in the tissue corresponding to that cancer type.
We used hierarchical clustering with cosine similarity. Kaplan-Meier survival analysis showed
that this clustering approach could separate patients with poor survival from those with better
survival (log-rank test, p < 0.05) for 6 out of the 10 cancer types (Fig 4, Supplementary S2 Fig,
Supplementary S10 Table).
Next, we repeated the analysis above using genes identified by LASSO for more than 5
drugs as a benchmark (Supplementary S10 Table). The Kaplan-Meier survival analysis was sig-
nificant for only 3 cancer types (log-rank test, p< 0.05), with the Lower Grade Glioma (LGG)
clusters having the smallest p-value equal to p = 0.013 (compare to 6 significant cases using
TG-LASSO and the log-rank p-value of the LGG clusters equal to p = 7.61E-13). These results
provide further evidence in favor of the role of the genes identified by TG-LASSO in the prog-
ress of the corresponding cancer type.
Functional and pathway enrichment analysis of LGG related genes
Since Kaplan-Meier analysis of LGG clusters obtained using TG-LASSO genes resulted in the
smallest p-value (log-rank test, p = 7.61E-13), we sought to further characterize the identified
genes that resulted in this significant patient stratification using functional and pathway
enrichment analysis. For this purpose, we used the KnowEnG’s gene set characterization pipe-
line [27] and identified 20 GO terms and two pathways enriched (FDR< 0.05) in this gene set
(Supplementary S11 Table).
Several of the most significantly enriched GO terms were related to extracellular matrix
(ECM), which plays an important role in the infiltration of glioma cells into the brain [48,
49]. Another important GO term was neutrophil degranulation (FDR = 2.1E-3). Neutrophils
are the most abundant type of white blood cells and the number of infiltrating neutrophils
has been shown to be associated with the malignancy of glioma and its drug resistance [50].
In addition, it has been shown that in patients with glioblastoma, neutrophil degranulation
is associated with peripheral cellular immunosuppression [51]. Another noteworthy GO
term was integrin binding (FDR = 0.037). Integrins are transmembrane proteins that
mediate cell adhesion, play an important role in promoting the invasiveness of glioma cells
[52], and have been suggested as potential targets with diagnostic and prognostic value in
glioma [53]. Several enriched GO terms were related to the activity of endopeptidases and
collagen. It has been shown that the level of collagen in glioma patients is increased, and it
also plays a key role in promoting the tumor progression [54]. Matrix metalloproteinases
(MMPs) are one important class of endopeptidases that are responsible for regulating the
turnover of collagens, and their expression and activity has been associated with the progres-
sion of human glioma [54, 55]. Finally, ‘response to drug’ was another enriched GO term,
which reflects the relevance of the identified genes to the general mechanisms of drug
response in a cell.
The enriched pathways included miRNA targets in ECM and membrane receptors
(FDR = 2.0E-3) and Syndecan-1-mediated signaling (FDR = 0.04). Syndecan-1 is a cell surface
heparan sulfate proteoglycan and its expression has been shown to be correlated with tumor
cell differentiation in various cancers [56]. In addition, its knockdown has been shown to
inhibit glioma cell proliferation and invasion and has been suggested as a therapeutic target
for glioma [57]. These results support our expectation that the LGG-related gene set not only
involves drug response related genes, but also includes those that play important roles in gli-
oma and may act as diagnostic biomarkers or therapeutic targets.
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Fig 4. The Kaplan Meier survival analysis results for six cancer types. Patients were clustered based on the expression of genes that were identified by
TG-LASSO for more than 5 drugs in the corresponding tissue. The p-value was calculated using a log-rank test.
https://doi.org/10.1371/journal.pcbi.1007607.g004
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Discussion
Ideally, a predictive model of CDR should be trained on data obtained directly from patients.
Similarly, identification of biomarkers of drug sensitivity has the most potential clinical impact
when based on patient data. However, since in practice most patients only receive the ‘stan-
dard of care’ treatment based on their specific cancer type, CDR data is scarcely available for
the newly approved drugs or drugs that have not yet passed the clinical trial, limiting our abil-
ity to decipher the mechanisms of drug sensitivity for these drugs. An alternative approach is
to train ML models on preclinical samples (e.g. CCLs) to predict the CDR of patients, then use
these predictions to discover novel biomarkers and druggable targets.
Recent large-scale studies that have cataloged the molecular profiles of thousands of CCLs
and their response to hundreds of drugs [15–17] are great resources to achieve this goal. In
this study, we adopted such an approach and systematically assessed a variety of linear and
non-linear single-task and multi-task ML algorithms. Our analyses showed that the CDR of
many drugs can be predicted using ML models (especially, regularized linear models) trained
on CCLs. However, by evaluating a variety of methods that include auxiliary information (e.g.
interaction of the genes, the tissue of origin, etc.), we observed that improving the performance
beyond what is achievable using linear models is extremely difficult and requires careful
modeling and novel computational techniques. It appears that the way by which auxiliary
information is utilized has a large impact: for example, several methods that include the tissue
of origin did not improve the results obtained by LASSO, and only TG-LASSO could improve
the performance. Additionally, we showed that TG-LASSO identifies tissue-dependent gene
sets for each drug that include various targets of the drug, genes involved in the drug’s mecha-
nism of action, and genes whose under- or over-expression could sensitize cancer cells to the
drug. Moreover, these sets include genes that are involved in cancer progression and are asso-
ciated with patient survival. These results suggest that in addition to a superior drug response
prediction performance, TG-LASSO can identify biomarkers of patient survival and drug
sensitivity.
Another important factor that played an important role in the performance of the ML mod-
els was data homogenization and batch-effect removal. The performance of TG-LASSO and
LASSO both deteriorated when we did not remove the existing batch-effect between the train-
ing dataset and the test dataset. In spite of this, TG-LASSO could distinguish between resistant
and sensitive patients for four drugs, when applied to non-homogenized data. This suggests
two approaches when dealing with scenarios in which new test samples arrive. The first
approach is to simply use the model trained on non-homogenized preclinical samples and
accept the worse performance. The alternative is to retrain the model every time a new test
sample arrives. This allows for training and prediction on homogenized data, but significantly
increases the computational cost. An alternative could be developing a new data homogeniza-
tion and batch effect-removal method that only transforms the gene expression of the test sam-
ples (keeping the gene expression profiles of training samples unchanged) by mapping them to
the subspace spanned by the training samples. However, the development of such a method is
beyond the scope of this study.
We note that due to the major differences between CCLs and tumors (e.g. the greater het-
erogeneity of cells in a tumour compared to CCLs), obtaining more accurate results based on
classical ML techniques may not be possible. The reason is that classical ML methods assume
that the training samples and the test samples are drawn from the same or similar distribu-
tions. While batch-effect removal and other homogenization and normalization techniques
help to alleviate this issue, more realistic preclinical models of cancer are necessary to signifi-
cantly improve these results. Recent advances in developing human derived xenografts [58]
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and 3D human organoids [59] may enable developing a more accurate predictive model of
CDR in cancer. However, due to the current high cost of these models, a more practical
approach is developing computational methods that explicitly model these differences. Such
methods must go beyond utilizing bulk gene expression data and take advantage of multi-
omics analysis of bulk and single-cell sequencing profiles of samples. Due to the rapid
advances in these domains, we expect that large databases of single-cell multi-omics profiles
of preclinical and clinical samples and their drug response will become available in the near
future.
Methods
Datasets, preprocessing and batch effect removal
We obtained the gene expression profiles (FPKM values) of 531 primary tumor samples of
TCGA patients who were administered any of the 23 drugs mentioned earlier. First, we
removed genes that contained missing values. We also removed any gene that was not
expressed (i.e. FPKM<1) for more than 90% of the samples. Then, we performed a log-trans-
formation and obtained log2(FPKM+0.1) values for each gene. The resulting gene expression
matrix contained 19,437 genes and 531 samples. We obtained the CDR of these patients from
the supplementary files of [6] (see the original paper for their approach in curating this data
from TCGA). Similarly, we obtained the Robust Multi-array Average (RMA)-normalized
basal gene expression profiles and the logarithm of half maximal inhibitory concentration, log
(IC50), of 979 cancer cell lines from GDSC (Supplementary S1 Table) for 17,737 genes.
To homogenize the gene expression data from these two datasets, we first removed genes
not present in both datasets as well as genes with low variability across all the samples (stan-
dard deviation < 0.1), resulting in a total of 13,942 shared genes. Then, we used ComBat [20]
for batch effect removal to homogenize the gene expression data from TCGA (RNA-seq) and
GDSC (microarray). This approach, which has been previously used to successfully homoge-
nize these two data types [21], removed the batch effect present in the gene expression datasets
(see Supplementary S1 Fig). For all follow-up analysis, we performed z-score normalization
on each gene across all the samples to ensure a mean of zero and a standard deviation equal to
one.
For the network-guided analyses, we downloaded four networks of gene interactions in
humans from the KnowEnG’s knowledgebase of genomic networks [27] (https://github.com/
KnowEnG/KN_Fetcher/blob/master/Contents.md). The details of each network including the
number of nodes and edges are provided in Supplementary S1 Table.
Machine learning regression models
The baseline models (Table 1) were all implemented using Scikit-learn [60] in Python and the
hyperparameters were selected using cross validation (using only CCL samples from GDSC).
The multi-task learning methods (MTL-LASSO and MTL-ElasticNet) require availability of
training drug response values for all drugs and all samples. Since the training drug response
matrix contains missing values, to obtain the results reported in Table 1 we used the ‘average
strategy’ (average of the drug response values across cell lines of a single drug) to impute the
missing values. We also tried a different approach (i.e. dropping cell lines with missing values),
but since the results were much worse, we did not include them in Table 1.
For the network-based algorithms (Table 4), we used four networks summarized in Supple-
mentary S1 Table. We used the normalized graph Laplacian of these networks to run GELnet
[32]. This method forces neighboring genes in the graph to have similar weights in order to
guide drug response prediction. Specifically, it defines a regularization penalty R(w) for the
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standard linear model.







where d and P are additional penalty weights for individual features and pairs of features,
respectively. Our basic GELnet implementation sets P = L and d = 0. Furthermore, we used
Network-Induced Classification Kernels (NICK), a method closely related to GELnet. The
NICK framework is actually a special case of the GELnet, with P = (I + βL) for some β� 0 and
d = 0. The parameter β provides a trade-off between graph-driven regularization and the tradi-
tional ridge regression penalty of the SVMs.
In addition to the above methods that utilize the graph Laplacian of each network in the
regression algorithm, we used sparse group LASSO (SGL). This method takes a collection of
pathways as input and induces sparsity at both the pathway and the gene level to generate the
input. We performed community detection on each of the networks in Table 4 by maximizing
the modularity using the Louvain heuristics [61] to identify gene sets to be used in the SGL
algorithm. We then ran SGL by fitting a regularized generalized linear model with group
memberships of genes as deemed by the community detection to predict drug response.
Finally, we developed a heuristic method based on ssGSEA [35] followed by LASSO. In
this method, we used ssGSEA to assign a score to each sample for the enrichment of its gene
expression profile in communities of each network, obtained earlier. These scores where then
used as features to train a LASSO model for prediction of CDR.
Methods for including tissue of origin in CDR prediction
In the first approach (Method 1 in Table 5), we augmented the gene expression profile of each
sample (both CCLs and tumors) with binary features corresponding to different tissues of ori-
gin shared between the TCGA and GDSC samples (a total of 13 features). For each sample its
tissue of origin was assigned a value of ‘1’, and other tissues were assigned a value of ‘0’. Then,
the LASSO algorithm was used to train a drug response model on CCLs and predict the CDR
of tumors.
In the second approach (Method 2 in Table 5), we trained different LASSO models for each
drug-tissue pair (23 drugs and 13 tissue types). More specifically, to predict the CDR of drug d
in a tumor of tissue t, we trained a LASSO regression model using the log (IC50) of drug d in
only cell lines corresponding to tissue t (i.e. a subset of the training samples). For tumors origi-
nating in tissues without matching training CCLs, we used all the CCLs to train the model.
Prediction of CDR in cancer tumors using Tissue-guided LASSO
TG-LASSO is a method for predicting the CDR of tumors using the information in all training
samples (originating from different tissue lineages), while incorporating information on the
tissue of origin of the samples. By utilizing all the training samples, it overcomes the lack of
generalizability stemming from limited number of CCLs from each tissue type, a major issue
in Method 2 above. In addition, by incorporating the information on the tissue of origin of the
samples in the training step, it improves the performance of tissue-naïve regression methods,
such as those in Table 1.
During training, LASSO minimizes the objective function 1
2n ky   Xwk
2
2
þ akwk1, where n
is the number of training samples, y is the response vector of length n, X is an n ×m feature
matrix (m is the number of features), k k2 denotes the L2 vector norm, k k1 denotes the L1 vec-
tor norm, and α is the hyperparameter that determines the sparsity of the model (i.e. number
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of features used in training). The hyperparameter tuning is usually achieved independent of
the structure of the training samples (e.g. their tissue of origin), for example using random
cross-validation or a regularization path. However, we and others [62] have shown that includ-
ing the group structure of data in selecting the hyperparameter is important in assessing the
generalizability of regression models. Motivated by these results, even though TG-LASSO uti-
lizes the gene expression and the drug response of all CCLs in training, the hyperparameter α
is selected in a tissue- and drug-specific manner, as explained below.
Let D be the set of all drugs and T be the set of all tissues in the test set (i.e. the TCGA dataset).
To train a model to predict the CDR of tumor samples from tissue t 2 T to drug d 2 D, we iden-
tify all the training CCLs corresponding to tissue t and use them as the validation set. In addi-
tion, we use all other CCLs as the training set. Then, the hyperparameter α is selected as the one
that obtains the best accuracy on predicting the log (IC50) values of the samples of tissue t in the
validation set. Designing the hyperparameter-tuning step such that the validation and the test
sets have the same tissues of origin ensures that the value of α is selected so as to generalize well
to the test set. The obtained value of α is then used with all CCLs (including those from tissue t)
to fit a model minimizing the LASSO objective function. In the prediction step, this fitted model
is then used with the gene expression of tumor samples from tissue t to predict their CDR.
Precision@k%
To further assess the performance of TG-LASSO, we defined a measure called Precision@k%
(motivated by Precision@k in information retrieval). To define Precision@k%, we first used
the log(IC50) values of the preclinical cell lines form GDSC to find the Kth percentile (K< =
50) and the (100-K)th percentile of each drug (separately), denoted as tK and t100-K, respec-
tively. Then, given the predicted log(IC50) values of the tumors and their annotation as ‘sensi-
tive’ or ‘resistant’ (based on their known CDR), we defined
Precision@k% ¼
R100  K þ SK
N100  K þ NK
;
where R100−K is the number of resistant tumors whose predicted log(IC50) is larger than t100
−K, SK is the number of sensitive tumors whose predicted log(IC50) is smaller than tK, N100−K
is the total number of tumors whose predicted log(IC50) is larger than t100−K, and NK is the
total number of tumors whose predicted log(IC50) is smaller than tK. Intuitively, this measure
shows the precision of predicting the tumors with predicted log(IC50) values larger than t100-K
as resistant and those with predicted log(IC50) values smaller than tK as sensitive. Note that
due to this definition of Precision@k%, for some values of k, the denominator may be equal to
0 and the measure may not be defined.
Gene ontology and pathway enrichment analysis
We used the gene set characterization pipeline of KnowEnG analytical platform [27] for this
analysis, which utilizes Fisher’s exact test to determine the significance of enrichments. We
excluded GOs or pathways with too few genes, focusing only on those with more than 10
members. For the pathway analysis, we used the ‘Enrichr’ pathways [63] available on Kno-
wEnG. All p-values were corrected for multiple hypothesis testing using Benjamini-Hochberg
false discovery rate, available as part of the python module [64].
Software availability
An implementation of TG-LASSO in python, with appropriate documentation and input files,
is available at: https://github.com/emad2/TG-LASSO.
Clinical drug response prediction using TG-LASSO
PLOS Computational Biology | https://doi.org/10.1371/journal.pcbi.1007607 January 22, 2020 17 / 22
Supporting information
S1 Text. The supplementary methods, all the supplementary figures and their captions,
and the caption of supplementary tables.
(DOCX)
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S2 Table. The detailed drug response prediction performance of baseline methods for each
drug.
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S3 Table. The detailed drug response prediction performance of network-based methods
for each drug.
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S4 Table. The detailed drug response prediction performance of tissue-based methods for
each drug.
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S5 Table. The detailed drug response prediction performance of various methods for
drugs whose administration period overlapped with at least another drug (i.e. adminis-
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S6 Table. The detailed drug response prediction performance of TG-LASSO and LASSO
applied to non-homogenized data.
(XLSX)
S7 Table. The list of genes identified by TG-LASSO for each drug, ranked based on the
number of tissues in which they were identified.
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S8 Table. The evidence curated from literature for genes identified by TG-LASSO in all tis-
sues for cisplatin.
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S9 Table. The list of genes identified by TG-LASSO for each tissue, ranked based on the
number of drugs for which they were identified.
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S10 Table. The results of Kaplan Meier survival analysis on TCGA samples using genes
identified by TG-LASSO and LASSO.
(XLSX)
S11 Table. Gene ontology and pathway enrichment results for the top genes identified by
TG-LASSO for brain, used in the survival analysis of LGG samples.
(XLSX)
S1 Fig. The distribution of preclinical as well as tumor samples before (A) and after (B) batch
effect removal, depicted using principal component analysis (PCA) of their gene expression.
(TIF)
S2 Fig. The Kaplan Meier survival analysis corresponding to BRCA, COAD, LUAD, and
LIHC samples from TCGA. Patients were clustered into two groups using the expression of
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genes identified by TG-LASSO for more than 5 drugs in each tissue type.
(TIF)
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